ABSTRACT
Little is known about the natural history of Hepatitis E virus (HEV) infection in immunocompetent individuals. The prevalence, the course of infection and the occurrence of transmission by transfusion were investigated in multitransfused immunocompetent patients/blood donor pairs included in a longitudinal sample repository collection and followed up between 1988 and 2010. Ninety-eight subjects aged 6-89 years and suffering from acquired haemoglobinopathies were tested for HEV markers (IgM, IgG and RNA) in serial samples collected every 2 or 3 years. Eighteen patients (18.4%) were positive for HEV-IgG at baseline with a prevalence increasing from 12.5% below 26 years to 32% above 56 years. Nine patients remained IgG positive along the study and nine lost their antibodies after a mean follow-up of 7.4 years (1-22 years). One seropositive patient showed an increase of IgG level and RNA-HEV reappearance 1 year after inclusion, suggesting a reinfection and one seroconversion, probably acquired through blood transfusion was observed. This first longitudinal study including immunocompetent individuals confirms that HEV infection is common in Western Europe and that transfusion transmission occurs probably less frequently than expected. In addition, seroreversion and reinfection seem to be common. This suggests that the anti-HEV may not persist overtime naturally. However, repeat exposure to the virus related to the high prevalence of HEV infection may result in a sustainable specific IgG response.
Subject(s)
Disease Transmission, Infectious , Hepatitis E/epidemiology , Hepatitis E/pathology , Transfusion Reaction , Adolescent , Adult , Aged , Aged, 80 and over , Child , Female , France , Hepatitis Antibodies/blood , Humans , Longitudinal Studies , Male , Middle Aged , RNA, Viral/blood , Young AdultABSTRACT
The French pioneer for blood transfusion, who eventually organized the very early blood transfusion centers worldwide, went to imagine a scenario written in purpose for Charlie Chaplin, the unique character of "The Tramp" ("Charlot" in French). The movie Star was offered to feature a blood donation propagandist, and no longer the perpetual, well-known, "loser". This anecdote, besides being amusing, tells a lot on how Arnault Tzank encompassed all the difficulties in collecting blood enough to meet the demand, at all times; his proposal turns out to be extremely modern and questions nowadays marketing for blood donation.
Subject(s)
Blood Donors/history , Motion Pictures/history , Propaganda , Transfusion Medicine/history , Altruism , Blood Donors/psychology , France , History, 20th Century , Humans , Societies, MedicalABSTRACT
Anecdotes, such as found in the media and chiefly the humor journals and magazines aim at bringing revisited insights on society subjects, which can even be the most serious. Anecdotes reported here on blood transfusion and the transfusion environment, that were retrieved from French news released in the media press between the 1950s to 1980s give a view on what has been achieved since then, but also on what is at a standstill by some incapability in moving forward or in changing minds. Those anecdotes would be used to stimulate or refresh debates in transfusion related-ethics.
Subject(s)
Blood Donors/history , Mass Media/history , Altruism , Attitude to Health , Blood Donors/ethics , Blood Donors/psychology , France , History, 20th Century , Humans , Motivation , Public Opinion , Remuneration , Wit and Humor as TopicABSTRACT
Rapid diagnostic tests (RDTs) are routinely used in African blood centres. We analysed data from two cross-sectional studies representing 95 blood centres in 29 African countries. Standardized panels of sera containing varying concentrations of anti-human immunodeficiency virus (HIV) antibodies (Ab), hepatitis B virus antigen (HBsAg) and antihepatitis C virus (HCV) Ab were screened using routine operational testing procedures at the centres. Sensitivity of detection using RDTs was high for HIV Ab-positive samples, but low for intermediately HBsAg (51·5%) and HCV Ab (40·6%)-positive samples. These findings suggest that current RDT use in Africa could pose a hazard to blood safety.
Subject(s)
Blood Safety/methods , Diagnostic Tests, Routine/adverse effects , Hepatitis B/blood , Hepatitis C/blood , Mass Screening/adverse effects , Africa , Diagnostic Tests, Routine/methods , HIV Infections/diagnosis , HIV Infections/etiology , Hepatitis B/etiology , Hepatitis C/etiology , Humans , Mass Screening/methods , Serologic Tests/adverse effects , Serologic Tests/methodsABSTRACT
BACKGROUND AND OBJECTIVES: Serologic screening for the major transfusion transmissible viruses (TTV) is critical to blood safety and has been widely implemented. However, actual performance as measured by proficiency testing has not been well studied in sub-Saharan Africa. Therefore, we conducted an external quality assessment of laboratories engaged in transfusion screening in the region. MATERIALS AND METHODS: Blinded test panels, each comprising 25 serum samples that were pedigreed for HIV, HBsAg, HCV and negative status, were sent to participating laboratories. The panels were tested using the laboratories' routine donor screening methods and conditions. Sensitivity and specificity were calculated, and multivariable analysis was used to compare performance against mode of testing, country and infrastructure. RESULTS: A total of 12 African countries and 44 laboratories participated in the study. The mean (range) sensitivities for HIV, HBsAg and HCV were 91·9% (14·3-100), 86·7% (42·9-100) and 90·1% (50-100), respectively. Mean specificities for HIV, HBsAg and HCV were 97·7%, 97% and 99·5%, respectively. After adjusting for country and infrastructure, rapid tests had significantly lower sensitivity than enzyme immunoassays for both HBsAg (P < 0·0001) and HCV (P < 0·05). Sensitivity also varied by country and selected infrastructure variables. CONCLUSION: While specificity was high, sensitivity was more variable and deficient in a substantial number of testing laboratories. These findings underscore the importance of proficiency testing and quality control, particularly in Africa where TTV prevalence is high.
Subject(s)
HIV Infections/diagnosis , Hepatitis B/diagnosis , Hepatitis C/diagnosis , Quality Assurance, Health Care , Africa , Antibodies, Viral/blood , Antigens, Viral/blood , Blood Safety , Blood Transfusion , Donor Selection , HIV Infections/virology , Hepatitis B/virology , Hepatitis B Surface Antigens/blood , Hepatitis C/virology , Humans , Immunoenzyme Techniques , Laboratories/standards , Pilot Projects , Sensitivity and SpecificityABSTRACT
The current issues debate brings together experts around the themes of self-sufficiency (in its national and European aspects) and of needs in cellular blood products. The point of view of the manufacturer and prescribers of blood products are confronted.
Subject(s)
Blood Safety , Blood Banks , Blood Donors/supply & distribution , Blood Safety/standards , Blood Transfusion/statistics & numerical data , France , Health Services Needs and Demand , Humans , Prescriptions/statistics & numerical dataABSTRACT
This paper brings together the abstracts and proceedings of a seminar held on the topic of "ethics and transfusion", October 15, 2013 at the National Institute of Blood Transfusion, Paris.
Subject(s)
Blood Donors/ethics , Blood Transfusion/ethics , Ethics, Medical , Congresses as Topic , HumansSubject(s)
Biomedical Research , Blood Transfusion , Communicable Disease Control , Community Health Services , Africa South of the Sahara/epidemiology , Biomedical Research/organization & administration , Biomedical Research/trends , Blood Transfusion/methods , Blood Transfusion/standards , Blood Transfusion/trends , Communicable Disease Control/methods , Communicable Disease Control/organization & administration , Communicable Disease Control/standards , Communicable Disease Control/trends , Communicable Diseases/blood , Communicable Diseases/epidemiology , Community Health Services/methods , Community Health Services/organization & administration , Community Health Services/standards , Community Health Services/trends , Female , Humans , Male , Retrospective StudiesABSTRACT
Blood donation is an act of solidarity. Most often, this act is done on a volunteer basis and, depending on countries and circumstances, is not remunerated. The increase in need, the always-greater number of deferral criteria, the safety issues and the changes in the structures of our societies are among the many subjects for ethical debates. Taking these into account, the actors of the transfusion must analyze certain parameters: the value of a donation, the meaning of volunteering, the appropriateness of remunerating the act of giving a part of one's self, no longer as a donation or an expression of altruism and solidarity, but as a commercial act regimented by economic laws.
Subject(s)
Blood Safety , Blood Transfusion/ethics , Altruism , Anonymous Testing , Biological Products , Blood Donors/ethics , Blood Donors/legislation & jurisprudence , Blood Donors/psychology , Blood Safety/ethics , Blood Safety/methods , Blood Transfusion/economics , Blood Transfusion/legislation & jurisprudence , Blood-Borne Pathogens , Confidentiality , Developing Countries , Evidence-Based Medicine , France , Health Policy , Health Services Needs and Demand , Humans , Motivation , Organ Trafficking/ethics , Plasma , Remuneration , Risk Assessment , Social ResponsibilityABSTRACT
The current issues debate will bring together experts around the themes of self-sufficiency (in its national and European aspects) and of needs in cellular blood products. The point of view of the manufacturer and prescribers of blood products will be confronted.
Subject(s)
Biological Products/supply & distribution , Blood Banks/statistics & numerical data , Blood Safety , Blood Transfusion , Blood , Health Services Needs and Demand , Prescriptions , Biological Products/standards , Blood Banks/ethics , Blood Donors/supply & distribution , Blood Transfusion/standards , Erythrocyte Transfusion/standards , Europe , France , Health Policy , Humans , VolunteersABSTRACT
PURPOSE OF THE STUDY: Hemovigilance being an essential part of blood transfusion safety, many countries have set legislation for its organization and its establishment. In Sub-Saharan Africa, where transfusion practice is facing many challenges, hemovigilance does not always appear as a priority. Nevertheless, in 2000, Burkina Faso decided to reorganize its blood transfusion system according to the World Health Organisation recommendations and other international standards. A national blood transfusion center and regional blood transfusion centers were created. From 2005 to 2009, a hemovigilance pilot project was conducted by the regional blood transfusion center of Bobo-Dioulasso. METHODS: The implementation of this hemovigilance project included the following steps: training of medical and paramedical personnel of the health facilities provided with blood and blood products by the regional blood transfusion center, distribution of post transfusion and hemovigilance forms, and the creation of a hemovigilance and transfusion committee. RESULTS: During the period 2005-2009, 34,729 blood products were distributed for 23,478 patients. The return rate of the post-transfusion and hemovigilance forms (number of files completed partially or completely and returned to the regional blood transfusion center compared to the number of units distributed) raised from 83.1 to 94.8%, the rate of traceability (rate of forms returned to the regional blood transfusion center and totally completed) raised from 71.6 to 91.6%, and the concordance between the patient for which the blood was delivered and the patient transfused moved from 92.9 to 98.0%. The notification rate of transfusion incidents raised from 1.1 to 16.1 per 1000 units transfused during that period. CONCLUSION: The implementation of a hemovigilance system is possible in the Sub-Sahara African countries. This constitutes a major element in the improvement of different steps of transfusion safety. The implementation of a hemovigilance system requires negotiations between transfusion centers and the hospital personnel, and should be facilitated by the official regulation on blood transfusion practices.
Subject(s)
Blood Safety/statistics & numerical data , Blood Safety/standards , Burkina Faso , Humans , Pilot ProjectsABSTRACT
Pathogen reduction technology, now applicable to platelets and plasma, has limits that are already known, and potential or poorly defined other ones. We can distinguish limitations due to adverse events related to the technology itself or to recipient susceptibility, the limits of effectiveness depending on the target, the technology, organizational, economic and geographical limits.
Subject(s)
Blood-Borne Pathogens , Infection Control/methods , Transfusion Reaction , HumansABSTRACT
INTRODUCTION: In B-cell acute lymphoblastic leukemia (B-ALL), testing at diagnosis for BCR/ABL1 gene rearrangements is mandatory for prognostic stratification and treatment decisions. Several diagnostic methods have been proposed using flow cytometry to identify BCR/ABL1(+) B-ALL. METHODS: We evaluated expression of the myeloid antigen CD66c by flow cytometry in B-ALL. We studied 94 patients with B-ALL. The t(9;22)(q34;q11) or BCR/ABL1 rearrangement was detected by cytogenetic analysis or RT/PCR. Myeloid antigens CD66c, CD13, CD33, CD117, Myeloperoxidase, CD15 and CD65 were determined by flow cytometry. RESULTS: Of these 94 cases, 17 (18%) cases displayed BCR/ABL1 gene rearrangements and 38 (40%) cases were CD66c positive. CD66c was the most common myeloid antigen expressed on malignant lymphoblasts. Its expression was correlated with BCR/ABL1 rearrangements (P = 0.0001): sensitivity 82%, specificity 69%, positive predictive value 37% and negative predictive value 95%. Co-expression of CD66c(+) CD13(+) was more frequent in BCR/ABL1(+) B-ALL (29%) than BCR/ABL1(-) cases (4%) (P = 0.0044). Some BCR/ABL1(-) B-ALL cases (including hyperdiploid or cases with normal karyotype) were CD66c positive (31%). CONCLUSION: CD66c expression is correlated, but not specifically, with BCR/ABL1 rearrangement. It would seem better to interpret the absence of CD66c expression with a lack of BCR/ABL1 rearrangement. This myeloid antigen could be interesting in the detection of minimal residual disease.
Subject(s)
Antigens, CD/genetics , Antigens, CD/metabolism , Cell Adhesion Molecules/genetics , Cell Adhesion Molecules/metabolism , Gene Expression Regulation, Neoplastic , Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics , Precursor Cell Lymphoblastic Leukemia-Lymphoma/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Cohort Studies , Female , Fusion Proteins, bcr-abl/genetics , Fusion Proteins, bcr-abl/metabolism , GPI-Linked Proteins/genetics , GPI-Linked Proteins/metabolism , Gene Rearrangement/genetics , Humans , Male , Middle Aged , Neoplasm, Residual/genetics , Young AdultABSTRACT
In the different forms of art developed by Humanity over the centuries, artists have at times chosen themes from the world of medicine or health, such as blood donation or transfusion. In order to illustrate this, we have looked at three artistic domains: painting, movies and body art.
Subject(s)
Art , Blood , Motion Pictures , Blood Transfusion , Ceremonial Behavior , Fantasy , Female , Humans , Male , Medicine in the Arts , Menstruation , Postpartum Hemorrhage , Pregnancy , Symbolism , WarfareABSTRACT
The pioneers of blood transfusion first appeared in the 17th century, mainly in France and England, through animal experimentation, followed by some attempts in the healthy or sick. In France, the names of Dom Robert and Jean-Baptiste Denis belong to the beginning of the adventure of transfusion. Transfusions were then made with a total lack of knowledge of immunological danger. Following the death of a transfused patient, a death most likely related to acute intravascular hemolysis, the practice of transfusion was prohibited, on both sides of the Channel, by decision of Parliament.
Subject(s)
Blood Transfusion/history , Animals , France , History, 17th Century , HumansABSTRACT
The Canadian Frederick Banting (1891-1941), in discovering the existence of insulin, was able to treat, for the first time, with efficiency, diabetic patients. This discovery and its application did not happen easily, in particular within his own team. In 1922, the Nobel Prize would reward this researcher, who died two decades later in an airplane crash.
Subject(s)
Diabetes Mellitus/history , Hypoglycemic Agents/history , Insulin/history , Nobel Prize , Canada , Diabetes Mellitus/drug therapy , History, 20th Century , Humans , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , MaleABSTRACT
Pioneer in the field of hormone therapy, Charles-Edward Brown-Séquard (1817-1894) tried to stop the effects of aging on his contemporaries by injecting animal testicle extracts. His therapy was very popular in the last years of the 19th century. He even had followers in the following century, amongst whom Serge Voronoff (1866-1951), who grafted monkey testicles in replacement of human ones, or Paul Niehans (1882-1971) who practiced therapy using calf embryo cells in Switzerland.